

Curriculum Vitae

Personal information **Rebecca Cox**

Work experience

1. Employer: Haukeland University Hospital
 - Start date: 112011
 - End date:
 - Position: Head of Influenza Centre
 - Activities:
 - Country: Norway
2. Employer: University of Bergen
 - Start date: 091995
 - End date:
 - Position: Professor and Head of the Influenza Centre
 - Activities:
 - Country: Norway

Education and training

1. Subject: The London Hospital Medical College, University of London
 - Start date: 091990
 - End date: 031995
 - Qualification: PhD
 - Organisation: Influenza, vaccine, clinical trials, preclinical, clinical
 - Country: United Kingdom
2. Subject: Plymouth University
 - Start date: 091987
 - End date: 061990
 - Qualification: B.Sc. (Hons) First class Biological Sciences
 - Organisation: Influenza, virology, immunology
 - Country: United Kingdom

Additional information

Publications

175 total publications in high impact international peer reviewed journals 82 publications last 5 years / H-index 42, 10397citations (Google scholar H index 46, citations 10397) / Complete list of publications can be found [here](#)

Projects

Project management experience (Current) Cox has been a partner in 9 EU grants (Framework programmes (FP) 4, 5, 6, 7, H2020, Nanomedicines and Innovative Medicines Initiative (IMI)), 5 Research Council of Norway (RCN grants and coordinated 3 international consortia funded by RCN and 2 by Helse Vest. She was also a partner in KG Jebsen centre for Influenza Vaccine Research.

Year	Project owner - Project - Role - Funder
2025-27	NORDFORSK, Nordic Post-COVID Economic Impact Consortium Partner. Budget NOK 5 million
2023-26	KLINBEFORSK. <i>Rehabilitation of cognitive decline after COVID-19 (ReCover)</i> Partner. Budget NOK 20 million.
2021-27	EU IMI2 <i>Innovations to accelerate vaccine development vaccine development and manufacture (Inno4Vac)</i> . Grant Number 101007799. 41 partners. WP leader Budget: €18.6 million.
2021-25	EU H2020. <i>European Corona Vaccine Trial Accelerator Platform. (Vaccelerate)</i> . Grant no. 101037867 31 partners. National coordinator &

	WP leader Conducted 3 phase 2 clinical trials. Budget: €12 million.
2020-26	EU H2020 <i>Indo-European Consortium for Next Generation Influenza Vaccine Innovation</i> (INCENTIVE). 19 partners. PI children's vaccine clinical trial. Budget: €6 million
2020-22	Research Council of Norway (RCN)/Trond Mohn Foundation (TMF). COVID-19 in healthcare workers and the general population in Western Norway. 5 partners. Coordinator - RJ Cox. Budget: NOK 5 million
2020-21	Helse Vest. COVID-19 in healthcare workers and the general population in Western Norway. Grant number F-11628. Coordinator - RJ Cox. Budget: NOK 1.7 million
2019-26	RCN <i>An effectiveness trial (phase IV) to evaluate protection of children and pregnant women by influenza vaccine in rural Bangladesh</i> . Partner icddr,b Coordinator - RJ. Cox. Budget: NOK 16.9 million

Memberships

International Society of Respiratory Viruses
 Norwegian Society of Immunology
 Member of [The Norwegian Academy of Science and letters](#)

Other Relevant Information

Year	Description - Role
2025-	Editorial board Elsevier Vaccine journal (international)
2024-	EU HERA Group for Identification and Prioritisation (GIP) (international)
2024-	Advisor for WHO Public Health Research Agenda for Influenza Workstream 3 (international)
2023-	Member of WHO Technical Advisory Group on a value assessment of influenza vaccines (international)
2022-	Member of The Norwegian Academy of Science and letters (national)
2022-	Member European Medicines Agency Scientific Advisory Group Vaccines (international)
2021-24	Member European expert group on SARS-CoV-2 variants (international)
2021	Member of the study group National Academy of Science, Engineering and Medicine (NASEM), USA " Best practices for vaccine research and development for management of pandemic influenza " (international)
2020-	Leader of Bergen COVID-19 consortium, an interdisciplinary consortium in Western Norway responding to the COVID-19 pandemic with >2500 participants (regional)
2020-	Member of expert group on COVID-19 vaccines providing scientific advice to the Norwegian government (national)
2020-	Member of expert group of Norwegian National Knowledge programme on COVID-19 providing scientific advice to the Norwegian government (national)
2020	Scientific advisor to European Commission to assist the

	Group of Chief Scientific Advisors with the development of the policy-based Scientific Opinion on Pandemics (<i>international</i>)
2020-21	Scientific advisor to UK government on COVID-19 (<i>international</i>)
2019-	Task force member Influenza Vaccines Research and Development Roadmap (IVR) (<i>international</i>)
2019-	Deputy chair Influenza and Other Respiratory Viruses (board member since 2009) (<i>international</i>)
2019-	Member of European infrastructure for translational medicine (Eatris) vaccine platform (<i>network consisting of 80+ top tier centres in EU</i>) (<i>international</i>)
2019	Scientific advisor and panel moderator to World Health Organisation (WHO) Technical Consultation on better global tools: Product research and innovation for influenza prevention, control and treatment (<i>international</i>)
2018-	Senior Editor for the Blackwell journal Influenza and Other respiratory viruses (<i>international</i>)